Accuray Incorporated
ARAYAccuray Incorporated is a medical device company that develops, manufactures, and sells radiation therapy systems for cancer treatment. Known for its CyberKnife and TomoTherapy products, the company focuses on providing precise, minimally invasive radiation solutions to improve patient outcomes.
Company News
The global Robotic Radiotherapy Market is expected to grow from USD 1.15 Billion in 2023 to USD 3.18 Billion by 2032, driven by technological advancements in cancer treatment and increasing precision in radiotherapy systems.
The article explores the potential of AI and robotic technologies in surgical medicine, highlighting three companies positioned to lead this medical revolution through advanced robotic surgical systems and AI integration.
Accuray reported Q4 fiscal 2025 results with $128 million revenue, completed debt refinancing, and showed strong international market growth, particularly in emerging markets. The company issued fiscal year 2026 guidance of $471-$485 million in revenue.
Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
Accuray faces tough competition from Varian and Elekta, but is focusing on upgrading its installed base. Read why ARAY stock is a Buy.
